Graves' disease and thyroid functional autonomy in the region of mild iodine deficiency
https://doi.org/10.14341/ket20117451-55
Abstract
A comparative epidemiological analysis of patients with Graves’ disease (GD) and functional autonomy (FA), the thyroid gland in iodine deficiency region of Kabardino-Balkaria. The study included 168 patients with the syndrome of hyperthyroidism, from which, after the differential diagnosis of selected 65 patients with GD and 60 people with FA. Patients were divided by gender, age, area of residence (piedmont, mountains, plains). The peak of the disease accounts for GD, naturally, for 40–50 years, and FA-in older age groups – 60–70. The proportion of men is 24.6%, which reflects the relative rarity of GD males. Sensitivity of TBII is 96.9% and specificity, 91.6%. Given that some patients with FA is determined TBII (8.3%), the results can be interpreted only in conjunction with clinical data and instrumental methods.
About the Authors
A Ametovprofessor, zav. kafedroy endokrinologii i diabetologii GBOU DPO RMAPO Minzdravsotsrazvitiya Rossii
L Kondratieva
dotsent kafedry endokrinologii i diabetologii GBOU DPO RMAPO Minzdravsotsrazvitiya Rossii
L Bugova
assistent kafedry fakul'tetskoy terapii, meditsinskiy fakul'tet KBGU, Respublikanskaya klinicheskaya bol'nitsa
References
1. Балаболкин М.И., Клебанова Е.М. Креминская В.М. Дифференциальная диагностика и лечение эндокринных заболеваний: Руководство. М.: Медицина, 2002.
2. Бровкина А.Ф. Эндокринная офтальмопатия. М., 2004.
3. Валдина Е.А. Заболевания щитовидной железы. Изд. 3-е. СПб.: Питер, 2006.
4. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. М.: Гэотар-медиа, 2007.
5. Дедов И.И., Мельниченко Г.А. Пронин В.С. и др. Клиника и диагностика эндокринных нарушений. М., 2005.
6. Дразнин Н.М. Радиоактивный йод в клинике. Минск, 1961.
7. Трошина Е.А., Платонова Н.М., Юшков П.В., Солдатова Т.В. Заболевания щитовидной железы. Ультразвуковая и морфологическая диагностика. М., 2008. 50–52.
8. Фадеев В.В. Заболевания щитовидной железы в регионе легкого йодного дефицита. М.: Видар, 2005. 14–15.
9. Eckstein A.K., Plicht M., Lax H., Neuhauzer M. et. al. Thyrotropin receptor autoantibodies are independent risk factors for Graves, ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol.Metab. 2006; 91: 3464–3470.
10. Davies T.F. Newer Aspects of Graves’ Disease. Bailliere’s Clin. Endocrinol. Metab. 1997; 11: 431–601.
11. Davies T.F., Roti E., Braverman L.E., DeGroot L.J. Controversy-Thyroid stimulating antibodies. J. Clin. Endocrinol. Metab. 1998; 83: 3777–3785.
12. Hedley A.J., Yong.R.E., Jones S.J., Aleksander W.D. Antithyroid drugs in the treatment of hyperthyroidism of Graves, diseas: long-term follow-up of 434 patients. Clin. Endocrinol. 1989; 31: 209–218.
13. Prummel M.F. Recent Developments in Graves, Ophthalmopathy. Kluwer Academic Publishers. Boston, USA, 2000.
14. Rapoport B., McLachlan S.M. Graves’ Disease: Pathogenesis and Treatment, Kluwer Academic Publishers. Boston, USA, 2000.
15. Smith Rees B. Hall R. Thyroid–stimulating immunoglobulins in Graves,diseas. Lancet 1974; 2: 427–431.
16. Pedersen I.B., Knudsen N., Perrild H. et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves, disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin.Endocrinol. 2001; 55: 381–390.
Review
For citations:
, , Graves' disease and thyroid functional autonomy in the region of mild iodine deficiency. Clinical and experimental thyroidology. 2011;7(4):51-55. (In Russ.) https://doi.org/10.14341/ket20117451-55
Views:
1167
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
